Effect of Prophylaxis With Low-Dose Anti-Thymocyte Globulin on Prevention of Acute Kidney Allograft Rejection

Transplantation Proceedings

Volumn 40, Issue 1, 2008, Pages 137-139

  Khosroshahi, H T ^b   Tubbs, R S ^c   Shoja, M M ^a   Ghafari, A ^a   Noshad, H ^a   Ardalan, M R ^a  

^a UNIVERSITY OF TABRIZ   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FISHER EXACT TEST; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROPHYLAXIS; STUDENT T TEST;

ACUTE DISEASE; ADULT; ANTILYMPHOCYTE SERUM; BLOOD UREA NITROGEN; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 38749129102     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.12.016     Document Type: Article

References (13)

1. Kaden J. Optimal management of induction therapy with ATG in kidney allograft recipients. Int J Immunother 15 (1999) 115
2. Bock H.A., Gallati H., Zurcher R.M., et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Freseius versus OKT3 after renal transplantation. Transplantation 59 (1995) 830
3. Norman D.J., Shield C.F., Barry J., et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis 9 (1988) 107
4. Kahana L., Navarte J., Ackermann J.R., et al. OKT3 prophylaxis versus conventional drug therapy: single center perspective, part of multicenter trial. Transplant Proc 15 (1989) 5
5. Norman D.J., Kahana L., Stuart F., et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55 (1993) 44
6. Kaden J. Eleven years intraoperative ATG bolus. A list of successes. Ann Transplant 7 (2002) 4
7. Schulz T., Flecken M., Kapischke M., et al. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results. Transplant Proc 37 (2005) 1818
8. Lange H., Muller T.F., Ebel H., et al. Immediate and long term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transplant Int 12 (1999) 2
9. Kaden J., May G., Muller P., et al. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival. Transplant Proc 27 (1995) 1060
10. Varghese Z., Abudher M.N., Fernando O.N., et al. Induction therapy with bolus ATG increase cyclosporine sensitivity in renal transplant recipients. Transplant Proc 33 (2001) 2251
11. Kaden J., May G., Strobelt V., et al. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 29 (1997) 344
12. Martins L., Fonseca I., Almeida M., et al. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc 37 (2005) 2755
13. Weimer R., Staak A., Susal C., et al. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int 18 (2005) 226